Myolimus™, a novel mTOR inhibitor macrocyclic lactone has demonstrated impressive versatility, stability, and a broad therapeutic index. The macrocyclic lactone drugs represent the most widely utilized drug family for drug eluting stent applications and have an established safety and efficacy profile. Myolimus can be used in a broad range of site–specific drug delivery therapeutic applications including a fully biodegradable stent program.
Four FIM Studies
Multiple iterations of Polmer and drug studies were completed to ultimately arrive at the current polymer and Novolimus combination on the Desyne Desyne BD and Desolve platforms.